Successful treatment of severe COVID-19 pneumonia, a case series with simultaneous interleukin-1 and interleukin-6 blockade with 1-month follow-up

Interleukin (IL)-6 and IL-1 blockade showed beneficial results in patients with severe COVID-19 pneumonia and evidence of cytokine release at the early disease stage. Here, we report outcomes of open-label therapy with a combination of blocking IL-6 with tocilizumab 8 mg/kg up to 800 mg and IL-1 rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Haibel, Hildrun, Poddubnyy, Denis, Angermair, Stefan, Allers, Kristina, Vahldiek, Janis L., Schumann, Michael, Schneider, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444821/
https://www.ncbi.nlm.nih.gov/pubmed/36071720
http://dx.doi.org/10.1177/1759720X221116405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444821/
https://www.ncbi.nlm.nih.gov/pubmed/36071720
http://dx.doi.org/10.1177/1759720X221116405

Ejemplares similares